title: The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer.
abstract: Targeting epidermal growth factor receptor (EGFR) is an important treatment option for non-small cell lung cancer (NSCLC). These targeted therapies have been studied extensively in NSCLC in first line and subsequent lines, including maintenance in empiric fashion or in patients with tumors harboring the EGFR mutations. In this manuscript, we will review in details the evolutions of these targeted therapy in the management of NSCLC.
authors.affiliation: Division of Adult Medical Oncology, Department of Oncology, King Abdulaziz Medical City for National Guard - King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. alolayanas@ngha.med.sa
authors.forename: Ashwaq
authors.initials: A
authors.lastname: Al Olayan
authors.forename: Hamad
authors.initials: H
authors.lastname: Al Hussaini
authors.forename: Abdul Rahman
authors.initials: AR
authors.lastname: Jazieh
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors